Sharemaestro company-news research for Eli Lilly and Company (LLY), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
MEX
Mexico
Provisional evidence
Company news sentiment
LLY news sentiment
Eli Lilly and Company
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score51Neutral is 50
Early balanced news score
34/100 evidence confidence
99% direct company focus
6 current stories across 3 publishers
Current company news
Early balanced news score
6 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone52/100
→
Published 30-day score51/100
Latest source headline
InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001
finance.yahoo.com · 12 Aug 2026 11:30
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
6 current stories are mapped specifically to LLY.
The score uses 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.512.
51/100
News scoreEarly balanced news score
35/100
Confidencethin evidence
99%/100
Company news6 company stories
87/100
Story agreement13/100 difference
News history
Daily score and story count over 30 days
15 Jul30 Jul13 Aug
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence10
0.512 after freshness weightingSource breadth60
3 independent publishersCompany relevance99
share tied directly to this companyFreshness68
recency-weighted evidenceAgreement87
how closely stories agreePublisher mix53
less reliance on one publisherPrice and news history
News score and weekly price over 26 weeks
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
07 Aug 202645MXN 20245.01+1.7%
31 Jul 202651MXN 19900.0-4.4%
24 Jul 202651MXN 20820.85+0.4%
17 Jul 202653MXN 20736.24+0.1%
10 Jul 202651MXN 20708.48-1.5%
03 Jul 202651MXN 21029.0-0.5%
26 Jun 202650MXN 21142.75+10.4%
19 Jun 202651MXN 19148.82-2.6%
Provisional evidence
News subjects
What is shaping the score
Regulatory and legal523 stories · 50%
Market update503 stories · 50%
Source mix
Where the evidence comes from
finance.yahoo.com424 stories · 67%
nasdaq.com671 stories · 17%
MarketBeat501 stories · 17%
Recurring subjects
Subjects appearing most often
Pharma4Clinical Trials3Biotech3Regulation2Fda Approval2Obesity Treatment1Net Income1Lawsuit1Healthcare1Financial Results1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
19 Jun50 neutral13 Aug 22:54
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 13 Aug 22:54 | 53 | +0 | 57/100 (-4) | 64 (-1) | Measured |
| 12 Aug 23:59 | 53 | -2 | 61/100 (+3) | 65 (+11) | Measured |
| 11 Aug 23:59 | 55 | +2 | 58/100 (+5) | 54 (+11) | Measured |
| 10 Aug 23:59 | 53 | +0 | 53/100 (+12) | 43 (+14) | Measured |
| 09 Aug 23:59 | 53 | +2 | 41/100 (0) | 29 (0) | Measured |
| 08 Aug 23:59 | 51 | +6 | 41/100 (+5) | 29 (-1) | Measured |
| 07 Aug 23:59 | 45 | -5 | 36/100 (+5) | 30 (+1) | Provisional |
| 05 Aug 23:59 | 50 | +0 | 31/100 (0) | 29 (+1) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#150Tone
finance.yahoo.comDirect company coverageStored article
InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001
IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company SEATTLE & CAMBRIDGE, Mass., August 12, 2026--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane pro
Antibody Drug ConjugatesBiotechCancerClinical Trials
- Published
- 12 Aug 2026 11:30
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Company discussed · 86%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.6% · 1.5d old
- Duplicates
- 1 consolidated
#250Tone
finance.yahoo.comDirect company coverageStored article
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business—social media and e-commerce platforms, credit card companies, payment processors an
Clinical TrialsFda ApprovalHealthcarePharmaRegulation
- Published
- 12 Aug 2026 09:30
- News subject
- Regulatory and legal
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 17% · 1.6d old
- Duplicates
- 1 consolidated
#350Tone
MarketBeatDirect company coverageScored from headlineSource lookup
Eli Lilly and Company (NYSE:LLY) CAO Sells $2,370,020.00 in Stock
- Published
- 11 Aug 2026 21:19
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.9% · 2.1d old
- Duplicates
- 1 consolidated
#435Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?
The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trial
Clinical TrialsFinancial ResultsLawsuitNet IncomeObesity TreatmentPharma
- Published
- 11 Aug 2026 12:44
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- High · 31.2% · 2.5d old
- Duplicates
- 1 consolidated
#550Tone
finance.yahoo.comDirect company coverageStored article
Veeva Vault CRM Selected by Eli Lilly and Company
PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of applications that provides the technology foundation for agentic commercial, the new commercial model that leverages AI to get the right medicines to more patients. "We are excited to expand our strategic work with Veeva by moving to Vault CRM," said Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly.
BiotechCrmPharma
- Published
- 11 Aug 2026 11:03
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 4.7% · 2.6d old
- Duplicates
- 1 consolidated
#667Tone
nasdaq.comDirect company coverageStored article
Eli Lilly's Foundayo Wins UK Approval
(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory Agency (MHRA) on August 10, 2026, follows the U.S. FDA's approval in April 2026, positioning Foundayo as a key entrant in the competitive obesity and diabetes market. Foundayo (orforglipron) is a small-molecule GLP-1 receptor agonist designed for convenient daily use without food or water restrictions. Clinical data
BiotechDiabetesEarningsFda ApprovalPharmaRegulation
- Published
- 11 Aug 2026 07:30
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- High · 35.7% · 2.7d old
- Duplicates
- 1 consolidated
Earlier company news
LLY news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Aug
12
2026
finance.yahoo.comArchivedNegative tone
Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales
DowngradeEarningsPharma
- Published
- 12 Aug 2026 18:29
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
12
2026
finance.yahoo.comArchivedNegative tone
Eli Lilly Stock Falls While Retatrutide Lawsuits Expand
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase 3 trials. Yet Lilly says compounding pharmacies, medical spas and online vendors are already pushing unauthorized versions for human use, sometimes hiding behind research use only labels. Lilly shares slipped roughly 0.8% Wednesday morning, but this fight is much bigger than one day's stock move. Lilly is defending a drug
Clinical TrialsLawsuitsObesityPharmaQuarterly Earnings
- Published
- 12 Aug 2026 18:24
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
12
2026
finance.yahoo.comArchivedPositive tone
Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci's recent early Phase 1 ABS-201 update and Eli Lilly's US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareh
Balance SheetBiotechClinical TrialsShare PriceShareholder
- Published
- 12 Aug 2026 18:11
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
12
2026
finance.yahoo.comArchivedNegative tone
Lilly Targets Black-Market Retatrutide Sellers
This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY fairly valued? Test your thesis with our free DCF calculator. The company filed six lawsuits against U.S. businesses it accuses of selling unapproved versions of the drug while it remains in clinical development. Retatrutide is still in Phase 3 trials for obesity, type 2 diabetes and related conditi
Clinical TrialsLawsuitsPharmaRegulation
- Published
- 12 Aug 2026 17:54
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
12
2026
finance.yahoo.comArchivedPositive tone
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo
DiabetesEarningsFourth QuarterGuidanceObesityPharma
- Published
- 12 Aug 2026 16:10
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
12
2026
finance.yahoo.comArchivedNeutral tone
Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?
Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20
EarningsGuidanceObesityOncologyPharmaRevenue Growth
- Published
- 12 Aug 2026 16:03
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
12
2026
nasdaq.comArchivedNeutral tone
1 Vanguard ETF That Outperforms the S&P 500 and Still Has Room to Run
Key Points The "Magnificent Seven" stocks account for over 53% of this Vanguard ETF. This has helped the ETF outperform the S&P 500 in 13 of the past 20 years. Sluggish performance among its top 10 holdings has slowed returns this year.10 stocks we like better than Vanguard Morningstar Growth ETF › The S&P 500 is the stock market's most important index, tracking the 500 largest American companies on the market. It has become the main benchmark investors use to measure their returns, with outperformance and underperformance largely dependent on how it compares. Although investing in an S&P 500
Consumer DiscretionaryETFGrowth StocksIndustrialsMarketsTech
- Published
- 12 Aug 2026 15:35
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
12
2026
finance.yahoo.comArchivedPositive tone
IBD 50 Stocks To Watch: Obesity Drug Giant Eli Lilly Offers New Buy Point
Obesity-drug giant Eli Lilly stock is approaching a new buy point as the ongoing stock market rally strengthens. Continue Reading
- Published
- 12 Aug 2026 15:29
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
12
2026
seekingalpha.comArchivedPositive tone
Lilly files six lawsuits to crack down on black market retatrutide weight-loss shots
[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Lilly escalated its fight against black-market retatrutide by filing six new lawsuits against U.S. sellers, including compounding pharmacies, medical spas, and online vendors, the drugmaker said Wednesday in a statement [https://seekingalpha.com/pr/20616057-lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal]. The company said retatrutide remains an investigational Phase 3 molecule, and no retatrutide medicine has been approved for human use by any regulator worldwide. The FDA has made c
FdaPharmaRegulation
- Published
- 12 Aug 2026 10:41
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
12
2026
nasdaq.comArchivedNeutral tone
If I Were in My 40s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever
Key Points Warren Buffett steered the Berkshire Hathaway holding company to market-crushing returns for 60 years. He often said everyday investors could do well by simply buying an exchange-traded fund that tracks a diversified index like the S&P 500. In February 2014, he specifically recommended the Vanguard S&P 500 ETF because of its ultra-low fees, and it could help investors achieve a secure retirement. 10 stocks we like better than Vanguard S&P 500 ETF › Warren Buffett served as chief executive officer of the Berkshire Hathaway(NYSE: BRKA)(NYSE: BRKB) holding company between 1965 and 2025
DiversificationEtfsFinancial PlanningLong Term InvestmentMarketsTech
- Published
- 12 Aug 2026 10:17
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
12
2026
finance.yahoo.comArchivedNegative tone
Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment – Has The Bull Case Changed?
Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, its prolactin receptor antibody, and a US$40 million investment and development support from Eli Lilly that extend its cash runway into the second half of 2028. Next, we'll examine how Eli Lilly's US$40 million investment and advisory role could reshape Absci's investment narrative around ABS-201.
BiotechClinical TrialsEarningsEarnings ReleaseRevenue Growth
- Published
- 12 Aug 2026 08:10
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
11
2026
finance.yahoo.comArchivedNeutral tone
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
Absci Corporation Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028 VANCOUVER, Wash. and NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended Jun
Balance SheetBiotechClinical TrialsFda ApprovalFourth QuarterShares Outstanding
- Published
- 11 Aug 2026 21:05
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
11
2026
finance.yahoo.comArchivedPositive tone
Eli Lilly Scores Major Win in Weight-Loss Drug Race
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry's fastest-growing markets. Warning! GuruFocus has detected 6 Warning Signs with INTC. Is LLY fairly valued? Test your thesis with our free DCF calculator.
Fda ApprovalObesityPharmaRegulation
- Published
- 11 Aug 2026 20:07
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
11
2026
finance.yahoo.comArchivedPositive tone
2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now
Space Exploration Technologies (NASDAQ: SPCX) has been perhaps the most talked-about stock on Wall Street since it completed the largest IPO ever in mid-June. Opinions on the company's prospects are divided. Some see an innovative company that has already disrupted the space travel industry and will continue to do so, and perhaps deliver life-changing returns in the process. Others see an overvalued stock that could eventually succumb to an avalanche of headwinds. Still others, like myself, split the difference: SpaceX's future looks very promising, and it could post strong returns over the lo
AdvertisingAIClinical TrialsEarnings GrowthEarnings Per ShareFinancial Results
- Published
- 11 Aug 2026 18:20
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
11
2026
finance.yahoo.comArchivedPositive tone
How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?
AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% of total revenues. Skyrizi sales jumped 24% year over year on an operational basis to $5.5 billion, while Rinvoq sales rose 23.7% to more than $2.5 billion. Both drugs benefited from strong demand and market-share gains across their approved indications, especially in the popular inflammatory
BiotechCompetitionEarningsFda ApprovalImmunology
- Published
- 11 Aug 2026 17:54
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
11
2026
finance.yahoo.comArchivedPositive tone
Lilly Takes Its Weight-Loss Pill Battle Overseas
This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's Wegovy tablet in one of Europe's biggest drug marketplaces.Foundayo will initially be provided by private prescription. Availability will be wider via the U.K.'s National Health Service, subject to a review of cost efficiency.Lilly is banking on convenience to help it catch up with Novo. You can take Foundayo
Fda ApprovalHealthcarePharmaUK Approval
- Published
- 11 Aug 2026 16:12
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
11
2026
seekingalpha.comArchivedNeutral tone
These stocks have some of Wall Street’s lowest short interest
[short sale] abluecup Stocks including Apple, Alphabet, Exxon Mobil, and JPMorgan are among the companies with relatively low short interest, according to a screen of stocks with market capitalizations above $2B. The screen includes stocks with short interest between 1% and 2% of shares outstanding, highlighting companies with relatively limited bearish positioning. Apple (AAPL [https://seekingalpha.com/symbol/AAPL]) has the lowest short interest in the screen at 1.00%, followed by Alphabet (GOOG [https://seekingalpha.com/symbol/GOOG]) and InnIO (INIO [https://seekingalpha.com/symbol/INIO]) at
Consumer GoodsEnergyFinancialsShares OutstandingShort InterestTechnology
- Published
- 11 Aug 2026 14:40
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
11
2026
finance.yahoo.comArchivedPositive tone
J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?
Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum remains supportive. When a stock trades above both averages, investors generally interpret it as evidence that buying interest is strong enough to keep the shares above their medium- and long-term trend levels.Zacks Investment Research Image Source: Zacks Investment Research This strong share price performa
EarningsInnovative MedicineLitigationMedtechPatent ExpirationShare Price
- Published
- 11 Aug 2026 14:12
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
11
2026
finance.yahoo.comArchivedPositive tone
Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly's updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the stock today. Much of this reset is tied to recent Street commentary that focuses on incretin and GLP-1 therapies, Q2 results, and the potential of assets like Mounjaro, Zepbound, retatrutide and Foundayo. As you read on, you will see how to track these moving parts and keep up with the evolving Eli Lilly narrative. Stay
DiabetesEarningsObesityPharmaPrice TargetPrice Target
- Published
- 11 Aug 2026 00:20
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
10
2026
finance.yahoo.comArchivedPositive tone
Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?
For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of a competitive advantage than an operational consideration. That shift creates a new question for investors. If domestic manufacturing becomes a larger determinant of pricing, regulatory flexibility, and suppl
FdaManufacturingObesity DrugsPharmaRevenue GrowthShareholder
- Published
- 10 Aug 2026 23:21
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
10
2026
nasdaq.comArchivedNeutral tone
Why Eli Lilly Topped the Market Today
Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly › Eli Lilly(NYSE: LLY) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of its star medications. That also provided plenty of optimism for these types of drugs, which have been hotly popular for years now. The popular pill The product in question is Lilly's Foundayo, its first weight
EuropeMarketsObesity TreatmentsPharmaRegulation
- Published
- 10 Aug 2026 23:13
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
10
2026
finance.yahoo.comArchivedPositive tone
Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?
The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare's fastest-growing markets. Yet another competitive advantage for investors to keep in mind is manufacturing. During the early stages of the GLP-1 boom, demand consistently exceeded supply. Shortages of Wegovy, Ozempic, Mounjaro, and Zepbound demonstrated that developing a breakthrough medicine is only part of the challenge. Companies must also manufacture those medicines reliably, expand production fast enough to meet demand, and build enough capacity to support the next generation of therapies. That raises an important question for investors. As the obesity market matures, will the competitive advantage belong to the company with the strongest drugs, or the one with the strongest manufacturing platform? A specialized research team in white lab coats working together on a breakthrough biotechnological discovery. Bull Case Eli Lilly (NYSE:LLY) increasingly appears to view manufacturing as a long-term competitive advantage rather than simply a production necessity. Over the past several years, the company has committed tens of billions of dollars to expanding its manufacturing footprint across the United States. Rather than concentrating on a single facility, Lilly (NYSE:LLY) is investing across multiple manufacturing technologies, including active pharmaceutical ingredients, injectable medicines, and advanced therapies. This broader approach could give the company flexibility not only to support current demand for Mounjaro and Zepbound but also to manufacture future pipeline assets as they reach commercialization. That flexibility may become increasingly valuable. Today's obesity market is dominated by injectable therapies, but Lilly's (NYSE:LLY) pipeline extends well beyond its current products. Building capacity across multiple technologies today reduces the likelihood that manufacturing becomes a bottleneck tomorrow. The strategy also creates optionality beyond obesity. Manufacturing assets developed for peptide medicines, biologics, and advanced therapies can potentially support a much broader pharmaceutical portfolio. In other words, Lilly (NYSE:LLY) is investing in infrastructure that could generate value long after today's GLP-1 supply constraints disappear. Story Continues Lilly's (NYSE:LLY) manufacturing strategy also reflects a broader shift in how pharmaceutical companies think about competitive advantage. Historically, manufacturing was viewed as a support function that followed successful drug development. In the obesity market, however, manufacturing capacity has become a prerequisite for commercial success. The companies capable of supplying enough medicine can continue gaining market share, while those constrained by production risk leave demand unmet regardless of clinical performance. Novo Nordisk's (NYSE:NVO) strategy is different but no less compelling. Novo has continued expanding a production network that already includes decades of expertise in peptide manufacturing. The company has invested heavily in expanding its Clayton, North Carolina campus while strengthening its fill-finish capabilities through the acquisition of former Catalent facilities. Since three decades, the company has expanded nine times in North Carolina, invested nearly $6 billion dollars, built and upgraded two more facilities, and expanded its employee count from 50 to more than 2,000. In addition to expanding its U.S. footprint, the company's manufacturing network remains more geographically diversified than Lilly's (NYSE:LLY), which has historically been an advantage from an operational perspective. This approach also emphasizes manufacturing experience rather than manufacturing scale alone. Producing complex biologic me
MANUFACTURINGOBESITY-MARKETPHARMA
- Published
- 10 Aug 2026 22:39
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
10
2026
finance.yahoo.comArchivedPositive tone
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) received UK authorization for Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now
BIOTECHHEALTHCARE
- Published
- 10 Aug 2026 20:58
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
10
2026
finance.yahoo.comArchivedPositive tone
Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and type 2 diabetes. Lilly shares rose approximately 2.1% in regular trading. The appeal is easy to understand: no injection. Foundayo targets GLP-1 while giving patients an oral alternative to Lilly's blockbuster Mounjaro and Zepbound. The pill entered the U.S. market in April and generated $98 million in its latest reported quarter, versus the $105.6 million analyst estimate cited by Reuters. The U.K. approval expands the opportunity, but it does not automatically put Foundayo into patients' hands. NHS reimbursement and broader commercial access still have to follow. Warning! GuruFocus has detected 3 Warning Sign with MSFT. Is LLY fairly valued? Test your thesis with our free DCF calculator. That is where this gets interesting. Lilly does not need Foundayo to steal patients from Mounjaro or Zepbound. It needs the pill to make the market bigger. Some patients simply do not want injections, and a once-daily tablet removes that friction. Lilly already has the brand recognition, physician relationships and obesity-drug infrastructure to push a new format aggressively. But this will not be an uncontested runway. Novo Nordisk (NYSE:NVO) has oral Wegovy, turning the next GLP-1 battle into more than a race for weight-loss numbers. Convenience, pricing, supply, reimbursement and patient retention will matter. Lilly recently raised its 2026 revenue outlook to $85 billion to $87 billion, with Mounjaro and Zepbound doing much of the heavy lifting. If Foundayo develops into a third major franchise, Lilly's growth machine gets another cylinder.Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill·us.finance.gurufocus The valuation picture adds another twist. GuruFocus shows Lilly at $1,211.32 on Aug. 10 against a GF Value estimate near $1,500, putting the shares roughly 19.4% below that benchmark. That is a notable gap for a company already sitting at the center of one of pharma's biggest growth markets. Still, approval alone will not close it. Foundayo now has to produce prescriptions, reimbursement wins and sustained demand. If Lilly can turn a GLP-1 pill into another blockbuster while Mounjaro and Zepbound keep charging ahead, investors are no longer looking at one obesity winner. They are looking at an increasingly powerful franchise built around multiple ways to capture the same enormous market. View Comments
FDA-APPROVALGLP-1OBESITYPHARMAREVENUE-OUTLOOK
- Published
- 10 Aug 2026 20:35
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
10
2026
finance.yahoo.comArchivedPositive tone
Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY
During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the… Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these… I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on any weakness. Cramer's thesis highlights how mega-cap healthcare operators provide defensive shelter with strong dividend profiles and maintain high-growth product pipelines. Cramer further emphasized that innovation in biotechnology is driving tangible financial gains. He said: Amgen just racked up an excellent quarter. And credit where credit's due, time to accept that Moderna has begun to realize its stream of specialized vaccines for specific illnesses. Just last night, the company, it received FDA approval for its mRNA flu vaccine. Well, there's a reason why the stock's up 83% for the year.Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY Bristol-Myers Squibb Generates Trim Call Following Merger Rumors Later in the August 6 episode, a caller asked Cramer about Bristol-Myers Squibb Company (NYSE:BMY) after holding the stock through recent buyout speculation. In response, Cramer remarked: I actually, given how much that even an aggressive acquirer like AstraZeneca was willing to pay, it's probably worth it to trim. I just don't see as much upside. Look, it's not an expensive stock. It has a 3.9% yield, but there are others that are better, including J&J, which I like much more. A recent Financial Times report indicates that AstraZeneca held preliminary discussions regarding a potential purchase of US-based Bristol Myers Squibb. However, some believe that this is unlikely to happen and do not view it in a positive light. RBC analyst Trung Huynh noted that agreeing on valuation will be difficult given AstraZeneca's strong standalone growth target and BMY's patent cliff headwinds. Moreover, the firm believes that it needs to see more developments "before deeming a deal likely." Additionally, TD Cowen analyst Steve Scala showed a negative sentiment toward the deal, warning that BMY's severe patent risks would dilute AstraZeneca's long-term sales growth. The analyst noted that he sees short-term tailwinds due to synergies but showed less confidence for the longer-term. Story Continues Smart Money Positioning and Valuation Multiples Across Major Pharma Plays According to Insider Monkey's database, Eli Lilly and Company (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) hold the largest hedge fund backing among the group. Eli Lilly led during the first quarter of 2026 with 132 hedge fund positions, compared to 137 in the fourth quarter of 2025. Johnson & Johnson saw its hedge fund interest increase to 113 hedge funds in Q1 2026, up from 104 in the prior quarter. Meanwhile, Bristol-Myers Squibb Company (NYSE:BMY) tracked 83 hedge fund holders, rising from 82, while Amgen Inc. (NASDAQ:AMGN) recorded 65 hedge fund positions in Q1 2026, down from 70 in Q4 2025. Forward earnings ratios across the group show a wide split between premium growth plays and deeply discounted value names. Eli Lilly has the highest multiple in the group, trading at a forward price-to-earnings ratio of around 32.7x due to its market-leading GLP-1 franchise. Johnson & Johnson trades at 22.27x forward earnings, as it offers steady stability and balance sheet security. Amgen sits at 18.35x forward earnings, giving value-oriented investors a lower entry point into large-cap biotech execution. Bristol Myers Squibb remains the primary value play at a low forward P/E of 9.38x. However, limited growth catalysts support Cramer's recommendation to tr
BALANCE SHEETBIOTECHFDA-APPROVALFOURTH QUARTERHEALTHCAREM-A
- Published
- 10 Aug 2026 19:07
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
10
2026
finance.yahoo.comArchivedNeutral tone
Sector Update: Healthcare Stocks Rise in Afternoon Trading
Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
- Published
- 10 Aug 2026 18:40
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
10
2026
finance.yahoo.comArchivedPositive tone
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?
Immunocore Holdings plc IMCR offers a clear trade-off between commercial momentum and valuation risk. Kimmtrak continues to expand in metastatic uveal melanoma, while late-stage studies could open larger markets. The counterweight is equally clear. IMCR relies on one marketed product, trades above key industry valuation benchmarks and has seen a sharp deterioration in current-year earnings estimates. IMCR's Kimmtrak Growth Supports the Bull Case Second-quarter 2026 revenues rose 18.3% year over year to $115.9 million, driven by higher Kimmtrak volumes in the United States and international markets. First-half Kimmtrak sales increased 16% to $222.6 million, and management expects the drug's commercial momentum to continue through the rest of 2026. Kimmtrak's competitive position also has clinical support. Five-year phase III follow-up data showed a 16% overall survival rate versus 8% for the control arm in first-line HLA-A*02:01-positive metastatic uveal melanoma, reinforcing its role as the standard of care in eligible patients. Premium Sales Multiple Raises the Bar for IMCR IMCR trades at 3.3X forward 12-month sales, above the Zacks sub-industry's 2.0X and the sector's 2.2X. The premium means continued commercial execution and pipeline progress matter more because the stock already discounts more growth than its peer groups. That premium is not extreme relative to IMCR's own history, with a five-year median of 9.7X. Still, the current multiple leaves less room for disappointment if Kimmtrak growth slows or late-stage programs fail to expand the revenue base. IMCR Still Carries Single-Product Risk Kimmtrak generates all of Immunocore's product revenues. Any pressure from demand, pricing, competition, regulation or development setbacks could therefore have an outsized effect on the company's growth profile. The contrast with diversified oncology companies is useful. Eli Lilly LLY markets multiple cancer medicines across several tumor types, while Immunocore remains concentrated in one commercial asset. That concentration keeps execution risk elevated even as the pipeline advances. Immunocore Holdings PLC Sponsored ADR Price and ConsensusImmunocore Holdings PLC Sponsored ADR Price and Consensus Immunocore Holdings PLC Sponsored ADR price-consensus-chart | Immunocore Holdings PLC Sponsored ADR Quote Late-Stage Catalysts Could Reframe IMCR's Upside The phase III TEBE-AM study of Kimmtrak in advanced cutaneous melanoma could deliver top-line data as early as the end of 2026. Immunocore is also evaluating Kimmtrak in the phase III ATOM adjuvant uveal melanoma study, with enrollment expected to finish in 2028. Story Continues Brenetafusp adds another late-stage opportunity. Its registrational phase III PRISM-MEL-301 study is testing the candidate with Opdivo from Bristol Myers BMY in first-line advanced cutaneous melanoma. Bristol Myers has an established melanoma franchise around Opdivo, making the collaboration relevant to Immunocore's effort to broaden its oncology footprint. IMCR ended June with $880.2 million in cash, cash equivalents and marketable securities, giving it resources to support three phase III programs and other pipeline work. IMCR's Ratings Favor Patience Over Aggression IMCR's commercial progress and late-stage catalysts support the long-term case, but the valuation premium and single-product dependence argue against treating the stock as a straightforward buy at current levels. The balance of upside and execution risk supports a selective stance. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. IMCR has a Value Score of D, Growth Score of F, Momentum Score of F and VGM Score of F. The Zacks Rank suggests a neutral near-term stance, while the weak Style Scores do not add support from valuation, growth or momentum factors. For investors considering IMCR, patience may be more appropriate than aggressive accumulation until estimate t
EARNINGSONCOLOGYPHARMAPRICE-TARGET
- Published
- 10 Aug 2026 16:41
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
10
2026
finance.yahoo.comArchivedNeutral tone
This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.
New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading
- Published
- 10 Aug 2026 15:12
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
10
2026
finance.yahoo.comArchivedPositive tone
Lifespan Vision Ventures Leads Remedium Bio's Series A Financing
Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development. NORWALK, Conn., Aug. 10, 2026 /PRNewswire/ -- Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financing and has completed the round's initial closing, with participation from Eli Lilly and Company ("Lilly") and HKX Capital. In connection with the financing, Harry Robb of Lifespan Vision Ventures has joined Remedium's Board of Directors.LifeSpan Vision Ventures Remedium is developing durable protein therapeutics designed to enable controlled, long-lasting expression of therapeutic proteins following minimally invasive subcutaneous administration. The company's approach harnesses adipocytes as a durable site for therapeutic protein production, with the potential to provide multi-year benefit and adjustable dosing for patients with chronic diseases. The financing will support advancement of Remedium's lead programs, continued platform expansion, and preparation for first-in-human clinical studies. "Remedium has built a differentiated platform with the potential to address important limitations of chronic biologic therapy," said Andrew Worden, Founding Partner of Lifespan Vision Ventures. "We are proud to lead the Series A financing and support the company as it advances its pipeline toward clinical development and expands the potential of its platform." "Lifespan Vision Ventures shares our belief that durable therapies have the potential to fundamentally improve the treatment of chronic disease," said Frank Luppino, Chief Executive Officer of Remedium Bio. "We are excited to have them lead our Series A and to welcome Harry Robb to our Board as we advance our platform, expand our pipeline, and prepare for first-in-human clinical development." The financing follows recent progress across Remedium's pipeline, strategic collaborations, and preclinical programs, and is expected to support key milestones demonstrating the breadth of its platform across cardiometabolic and other chronic diseases. About Lifespan Vision Ventures Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven solutions that promote healthy aging and extend human healthspan. Contact: info@lifespanvision.com About Remedium Bio, Inc. Remedium Bio is a biotechnology company driven by the belief that any disease can be cured. The company develops life-changing therapeutics for large unmet medical needs by advancing a revolutionary gene therapy platform that enables safe, effective, and durable delivery of therapeutic genes with simple post-treatment dose adjustment. Remedium's proprietary Prometheus™ platform aims to replace many subcutaneously administered protein therapies with single-injection, adjustable gene therapies that offer long-lasting efficacy at a fraction of the cost. The company's pipeline includes programs targeting endocrinology, immunology, neurology, and musculoskeletal diseases. Story Continues For more information, please visit www.remedium-bio.com or contact info@remedium-bio.com Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lifespan-vision-ventures-leads-remedium-bios-series-a-financing-302847038.htmlCision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2026/10/c7377.html View Comments
BIOTECHCLINICAL-DEVELOPMENTGENE-THERAPYSERIES-A-FINANCING
- Published
- 10 Aug 2026 15:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
10
2026
finance.yahoo.comArchivedPositive tone
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock
Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength in non-COVID products continued to offset declining sales of its COVID products, Comirnaty (COVID-19 vaccine - in partnership with BioNTech [BNTX]) and Paxlovid (oral antiviral). Excluding sales from BioNTech-partnered Comirnaty and Paxlovid, revenues increased 5% operationally. Pfizer also raised the lower end of its 2026 revenue guidance, backed by continued strong performance of its new and acquired products. The company now expects revenues between $60.5 billion and $62.5 billion, compared with the previous range of $59.5 billion to $62.5 billion. The adjusted earnings guidance was reaffirmed at $2.80-$3.00 per share. However, the guidance now absorbs a 10 cents per share charge related to its licensing deal with Chinese biotech Innovent Biologics that will be recorded in the third quarter of 2026. However, a single quarter's results are not so important for long-term investors. To make an informed decision on whether to buy, sell or hold the stock, it is important to evaluate the company's fundamentals by examining its key strengths and weaknesses. First, let's understand the negatives. Declining Sales of PFE's COVID Products During the pandemic, Pfizer generated extraordinary COVID-related sales from Comirnaty and Paxlovid. Those revenues have fallen sharply as the pandemic faded. Sales of Pfizer's COVID products, Comirnaty and Paxlovid, came down to around $11 billion in 2024 and $6.7 billion in 2025 from $56.7 billion in 2022. Sales of Comirnaty are declining due to a narrow recommendation for COVID vaccines in the United States, while Paxlovid is experiencing reduced demand from lower infection rates. In 2026, Pfizer expects COVID-related revenues of approximately $4 billion, down from its previous forecast of $5 billion and below $6.7 billion generated in 2025. The decline reflects the continued normalization of COVID-19 infection rates and lower demand for COVID products. Consistent with this trend, sales of both Comirnaty and Paxlovid declined significantly during the first half of 2026. PFE's LOE Headwinds Pfizer faces a significant patent cliff later this decade. Pfizer expects a significant negative impact on revenues from the loss of exclusivity ("LOE") cliff in the 2026-2030 period as several of its key products, including Eliquis, Ibrance, Xeljanz and Xtandi, face patent expirations. The LOE cliff is expected to hurt sales by approximately $1.1 billion in 2026, which is slightly lower than the prior expectation of $1.5 billion. Story Continues PFE's 2026 Financial Outlook Dull Pfizer's revenue and earnings guidance for 2026 indicates mostly flat to slightly negative year-over-year growth. Pfizer expects total revenues for 2026 to be between $60.5 billion and $62.5 billion. The range represents a slight decline from 2025 revenues of $62.6 billion due to lower revenues from COVID products, Comirnaty and Paxlovid, and loss of revenues from the upcoming patent cliff. In 2026, Pfizer expects adjusted earnings per share in the range of $2.80-$3.00, which represents a decline from the 2025 EPS of $3.22 due to the dilutive impact of 3SBio and Metsera deals, lower COVID revenues and higher taxes. However, not everything is going wrong at Pfizer. Let's see the positives. PFE's Non-COVID Portfolio Driving Its Next Phase of Growth Pfizer's business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products. However, the company is gradually diversifying its portfolio through a combination of internal product launches like Abrysvo, Zavzpret, Elrexfio, Hympavzi, Litfulo and others, strategic acquisitions like Seagen, Metsera and Biohaven and the continued growth of several es
EARNINGSEARNINGS GROWTHEARNINGS PER SHAREOBESITYONCOLOGYPATENT-CLIFF
- Published
- 10 Aug 2026 14:17
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.